Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 15 , ISSUE 6 ( November-December, 2023 ) > List of Articles

ORIGINAL RESEARCH

A Clinical Trial of Oral Hydration Therapy for the Management of Very Preterm Nonsevere Preeclampsia

Amitha Vijay Kamat, Sucheta Suresh

Keywords : Mean arterial pressure, Oral hydration therapy, Preterm preeclampsia, Prolongation of pregnancy

Citation Information : Kamat AV, Suresh S. A Clinical Trial of Oral Hydration Therapy for the Management of Very Preterm Nonsevere Preeclampsia. J South Asian Feder Obs Gynae 2023; 15 (6):679-682.

DOI: 10.5005/jp-journals-10006-2354

License: CC BY-NC 4.0

Published Online: 04-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Background and objectives: To compare the effectiveness of oral hydration therapy compared with controls in decreasing mean arterial pressure and extending the duration of pregnancy in very preterm preeclampsia. Materials and methods: Forty-five cases of preterm preeclampsia between 20 and 34 weeks of gestation who were admitted to the Department of Obstetrics and Gynaecology, KIMS, Hubballi, were included in the study. They were randomized into two groups and intervened with oral hydration therapy and a control group, which was not on any intervention. Both groups were given adequate antihypertensives for control of BP. Outcome measures were a fall in BP, prolongation of pregnancy, and improved maternal and neonatal outcomes. Results: It was observed that diastolic BP significantly reduced in oral hydration group after 5 days of starting treatment (p = 0.020). The average weight of babies in oral hydration therapy group was 2.5 kg (p = 0.011) and 2 kg in controls. Mean prolongation of pregnancy among oral hydration group was 38.6 days (p = 0.037) and 26.7 days (p = 0.249) in controls. Conclusion: Oral hydration therapy was more useful to improve fetal outcome compared with maternal outcome. It was useful to prolong pregnancy and to increase fetal birth weight. It was not found as useful for improving maternal outcome or in decreasing mean arterial pressure. Though most of the outcomes were better in oral hydration therapy clinically, it was not statistically significant. Hence, larger studies maybe required to prove their difference in outcome.


HTML PDF Share
  1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: A WHO systematic analysis. Lancet Glob Health 2014;2(6):e323–e333. DOI: 10.1016/S2214-109X(14)70227-X.
  2. von Dadelszen P, Magee LA. Preventing deaths due to hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2016;36:83–102. DOI: 10.1016/j.bpobgyn.2016.05.005.
  3. Yadav S, Singh Y, Natu SM, et al. Serum levels of soluble Fms like tyrosine kinase-1 (sFlt-1) in normotensive and preeclamptic pregnancy. Int J Med Res Rev 2013;1(3):114–119. DOI: 10.17511/ijmrr.2013.i03.07.
  4. Thadhani R, Hagmann H, Schaarschmidt W, et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 2016;27(3):903–913. DOI: 10.1681/ASN.2015020157.
  5. Samartha Ram H, Sai Samyukta I, Nagasree V. Oral hydration therapy for the management of very preterm preeclampsia. IOSR J Dental Med Sci 2016;15(11):35–41. DOI: 10.9790/0853-1511083541.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.